榕树生物标记了保健(POC)的血液测试来诊断创伤性脑损伤(TBI)。榕树生物标志物的研究已经确定了独特的生物标记出现在病人的血液后的脑损伤。这些生物标志物的检测和量化可以提供早期迹象的脑外伤的早期干预和管理。

Actinobac生物医学是一个生物制药公司发展多个适应症的治疗,包括血液癌症,自身免疫/炎症性疾病和艾滋病。其药物候选人基于Leukothera (LtxA),天然蛋白质,目标和消除白血细胞(白细胞)参与许多疾病的机制。正在开发的产品基于Leukothera Actinobac治疗白血病/淋巴瘤、干眼病,牛皮癣。

ISA制药发展治疗各种癌症和传染病。它关注合成肽疫苗的开发,提高免疫系统识别特定的肽与特定类型的癌症和随后破坏肿瘤细胞。公司成立于2004年,位于Oestgeest荷兰。

Indena是一家致力于识别、开发和生产的活动原则来源于植物,用于制药、保健食品和化妆品行业。Indena、民营意大利公司约有700名员工,其中包括10%致力于全职研究,旨在培养管理,制造、分销业务在全世界40多个国家。Indena成功的关键是它的研究,包括:药用植物的药理筛选的好处;识别新的活跃的原则;提取和纯化系统的开发和工业应用的前沿。phyto-chemical研究进行Indena Settala自己的研究中心,意大利。Indena同样也与世界上最著名的大学和私人研究机构在生物的安全性和有效性临床评估阶段i的主要战略目标之一的医药研究开发新的积极的原则的应用程序。这也是一个不可缺少的保健食品和化妆品行业的基础。在制药行业Indena目前专注于抗癌治疗的发展,紫杉醇的成功后,以及在抗菌和抗病毒药物。还在研究是活跃的原则治疗病态和中枢神经系统功能障碍,如抑郁,焦虑,阳痿,睡眠障碍、感觉过敏。 Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

眼睛创新科学develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

Intarcia疗法是一种基于生物制药公司在波士顿,马萨诸塞州。Intarcia从事开发的管道产品的专有美第奇药物输送系统由三个技术:稳定技术,允许蛋白质、多肽、抗体片段,和其他高度有效的小分子是稳定在或高于人体温度,一个matchstick-sized渗透mini-pump放置在皮肤的真皮层提供药物,连续和一致的流动和放置技术包括专用工具旨在提供最优的用户体验。